PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

Date publication

mai 2025

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Dr EBERST Lauriane

Tous les auteurs :
Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frénel JS, Costaz H, Lebreton C, Pomel C, Colombo PE, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40349134

Résumé

Based on results of randomized clinical trials, polyADP-ribose polymerase inhibitors (PARPi) have become the standard of care in patients with platinum-sensitive recurrent ovarian cancer (OvC) in patients responding to platinum chemotherapy. However, little is known about their impact on survival in a real-world setting.

Mots clés

PARP inhibitor, maintenance therapy, platinum-sensitive, real word data, recurrent ovarian cancer

Référence

Oncologist. 2025 05 8;30(5):